Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Long-Term Deferred Tax (2017 - 2025)

Dr Reddys Laboratories (RDY) has 8 years of Long-Term Deferred Tax data on record, last reported at $129.7 million in Q1 2024.

  • For Q1 2024, Long-Term Deferred Tax rose 48.2% year-over-year to $129.7 million; the TTM value through Mar 2024 reached $129.7 million, up 48.2%, while the annual FY2024 figure was $130.2 million, 47.9% up from the prior year.
  • Long-Term Deferred Tax reached $129.7 million in Q1 2024 per RDY's latest filing, up from $87.5 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $168.6 million in Q1 2020 and bottomed at $87.5 million in Q1 2023.
  • Average Long-Term Deferred Tax over 5 years is $128.2 million, with a median of $129.7 million recorded in 2024.
  • Peak YoY movement for Long-Term Deferred Tax: soared 185.35% in 2020, then decreased 25.16% in 2022.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $168.6 million in 2020, then decreased by 13.53% to $145.8 million in 2021, then dropped by 25.16% to $109.1 million in 2022, then fell by 19.77% to $87.5 million in 2023, then skyrocketed by 48.2% to $129.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $129.7 million in Q1 2024, $87.5 million in Q1 2023, and $109.1 million in Q1 2022.